市场调查报告书
商品编码
1541557
2024-2032年按产品类型(祛痰药、止咳药/镇咳药、联合用药)、年龄组(儿童、成人)、配销通路(零售药房、医院药房、在线药房)和地区分類的止咳糖浆市场报告Cough Syrup Market Report by Product Type (Expectorants, Cough Suppressants/Antitussives, Combination Medications), Age Group (Pediatric, Adult), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), and Region 2024-2032 |
IMARC Group年全球止咳糖浆市场规模达59亿美元。上呼吸道感染(URTI)和其他呼吸系统疾病的发生率不断增加,以及在杂货店和药局容易买到止咳糖浆,主要推动了市场的成长。
主要市场驱动因素:更容易患呼吸系统疾病的老年人口的不断增加是市场的主要驱动力。此外,个人健康意识的增强也是另一个重要的成长诱导因素。
主要市场趋势:产品製造商正在推出采用天然成分和草药强化的增强型产品,具有增强免疫力的作用,这是推动全球市场的主要趋势之一。除此之外,副作用最小的止咳糖浆的推出进一步增强了市场。
地理趋势:由于该地区个人医疗保健支出能力的提高,亚太地区目前在全球市场中占据主导地位。除此之外,对咳嗽药物的日益关注正在对市场成长产生积极影响。
竞争格局:一些着名的止咳糖浆市场公司包括Acella Pharmaceuticals LLC、拜耳AG、葛兰素史克PLC、强生公司、辉瑞公司、Prestige Consumer Healthcare Inc.、利洁时集团PLC、赛诺菲、太阳製药工业有限公司和宝洁公司等。
挑战与机会:主要挑战,例如应对复杂监管环境的需求不断增加,以及对滥用和误用含有阿片类药物或其他精神活性成分的止咳糖浆的日益担忧,正在阻碍整个市场。然而,製药业的持续成长将在未来几年继续推动全球市场。
日益严重的医疗状况
感冒、流感、支气管炎、百日咳、气喘、慢性肺阻塞性疾病 (COPD) 和过敏的盛行率不断上升,推动了对止咳糖浆的需求。例如,根据《经济时报》2023 年发表的一篇文章,全球约有 3.39 亿人受到气喘影响。此外,由于烟草消费的增加和不健康的生活方式,咳嗽病例的增加也刺激了市场的成长。除此之外,根据世界卫生组织 (WHO) 的数据,每年有超过 800 万人因吸烟而过早死亡。其中,700万是直接吸烟者,170万是二手烟者。因此,政府和非政府组织正在发起众多计划和活动,以提高人民的意识。例如,2023 年 7 月,澳洲肺臟基金会发起了一项慢性咳嗽宣传活动,以提高成人和儿科的认识并支持诊断。除此之外,不断扩大的老年人口进一步影响了止咳糖浆的市场前景。例如,根据世界卫生组织的数据,2020年60岁及以上的人口将达到10亿,预计2050年将达到21亿人。
政府机构的监管环境
各国监管机构正在实施严格的规定,以确保止咳糖浆的领先公司遵守高医疗标准。据此,他们正在提高医疗保健专业人员开发仿製药的意识,从而催化止咳糖浆市场的近期机会。例如,在写给所有邦和中央直辖区的一封信中,印度药品监管总局(DCGI)要求确保印度生产的止咳糖浆达到全球标准质量,并对其进行详细验证。为此,他要求对丙二醇(PG)製造商、止咳糖浆製造商和进口商进行联合核查,以确保用于製造止咳糖浆的原料或供应符合全球协议。此外,世界卫生组织(WHO)也指出另一种止咳糖浆存在污染物。世界卫生组织在 2022 年 7 月收到有关可能受到污染的报告后,对特定批次糖浆的样本进行了测试。 Fourrts Laboratories 代表印度另一家名为 Dabilife Pharma 的公司生产止咳糖浆。这些严格的法规和检查将提高产品质量,预计将在未来几年推动止咳糖浆市场收入。
策略联盟
着名的关键参与者正在进行併购,并不断致力于新产品的开发,这些新产品通常由具有增强免疫力作用的天然成分和草药配製而成。这反过来又推动市场向前发展。例如,2023 年,葛兰素史克公司 (GSK plc)。与加拿大生技公司之一 Bellus Health 签署了 20 亿美元的收购协议。这笔交易的目的是加强葛兰素史克的临床产品组合和全球市场地位。该产品组合还包括糖浆和其他配方,从而提高了止咳糖浆的市场份额。同样,2023 年 12 月,美国 FDA 就默克公司针对治疗成人难治性慢性咳嗽(RCC)的药物之一吉法匹克新药申请(NDA)发布了完整回复函(CRL)。主要参与者正在进一步推出含有天然成分的止咳糖浆,以扩大其消费群,这是止咳糖浆市场的最新发展。例如,Vitae Health Innovation 推出了 VITATUSS,这是一种由接骨木浆果、百里香、木犀草、锦葵和沙棘萃取物配製而成的天然糖浆。同时,Sun Pharmaceutical Industries Ltd. 宣布推出一种名为 Chericof 12 的止咳配方。
IMARC Group提供了每个细分市场的主要趋势分析,以及 2024-2032 年全球、区域和国家层面的预测。我们的报告根据产品类型、年龄层和配销通路对市场进行了分类。
祛痰药
止咳药/镇咳药
联合用药
目前,止咳药/镇咳药占全球大部分市场份额
该报告根据产品类型对市场进行了详细的细分和分析。这包括祛痰药、止咳药/镇咳药和合併用药。报告显示,止咳药/镇咳药占最大的市场份额。
与感冒和咳嗽相关的症状通常可以透过使用非处方药 (OTC) 来控制。止咳药或镇咳药是用来控制和缓解咳嗽的药物。虽然许多镇咳药可以透过非处方药广泛获得,但也有一些镇咳药只能凭处方购买。镇咳药有多种剂型,例如胶囊、液体、片剂和糖浆。例如,在一项双盲交叉试验中,对美国最广泛使用的止咳药之一右美沙芬与欧洲传统镇咳药可待因进行了比较,该试验对16 名慢性咳嗽患者进行了主观和客观疗效评估。右美沙芬比可待因更能降低咳嗽强度,被大多数患者认为是更好的止痛药。反过来,这代表了推动止咳糖浆市场区隔的关键因素。
儿科
成人
成人目前占据最大的市场份额
该报告根据年龄组对市场进行了详细的细分和分析。这包括儿童和成人。报告称,成人占据最大的市场份额。
由于不健康的生活方式和大量接触烟草,成年人通常患有慢性和急性咳嗽。例如,根据欧洲呼吸学会2020年发表的研究,由于生活品质受损,约有10%的成年人患有慢性咳嗽。因此,不断扩大的成年人口正在增加止咳糖浆的市场需求,从而刺激止咳药物的采用。
零售药房
医院药房
网路药房
目前,零售药局在市场上占据明显主导地位
该报告根据配销通路对市场进行了详细的细分和分析。这包括零售药房、医院药房和网路药房。报告显示,零售药局占据了最大的市场份额。
根据止咳糖浆市场概况,由于其可及性和便利性,透过零售药房等分销管道可以轻鬆获得产品,这正在促进细分市场的成长。例如,根据德国药剂师协会联邦联盟(ABDA) 的数据,到2023 年,德国各地约有18,068 家社区药局满足医疗需求。治疗产品数量不断增加Stores Inc. 和沃尔格林 (Walgreens) 进一步成为另一个重要的成长诱导因素,此外,医院与这些连锁店的合作不断增加,也增强了止咳糖浆市场的近期价格。
北美洲
美国
加拿大
亚太
中国
日本
印度
韩国
澳洲
印尼
其他的
欧洲
德国
法国
英国
义大利
西班牙
俄罗斯
其他的
拉丁美洲
巴西
墨西哥
其他的
中东和非洲
根据止咳糖浆市场统计,亚太地区在市场上表现出明显的主导地位
市场研究报告还对所有主要区域市场进行了全面分析,其中包括北美(美国和加拿大);亚太地区(中国、日本、印度、韩国、澳洲、印尼等);欧洲(德国、法国、英国、义大利、西班牙、俄罗斯等);拉丁美洲(巴西、墨西哥等);以及中东和非洲。报告显示,亚太地区占据最大的市场份额。
区域市场主要由製药公司和政府组织之间的众多合作伙伴关係推动,通常是为了开发新型仿製药并提高个人和医疗保健专业人员的认识。此外,主要参与者正在强调创新的包装解决方案,这有助于市场的成长。除此之外,该地区个人支出能力的膨胀以及对预防性医疗保健的日益关注进一步验证了止咳糖浆市场的预测。根据 FMCG Gurus 的报告,自 COVID-19 大流行突然爆发以来,亚太地区超过 55% 的人更加自觉地增强免疫力。
The global cough syrup market size reached US$ 5.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 8.4 Billion by 2032, exhibiting a growth rate (CAGR) of 3.8% during 2024-2032. The increasing occurrence of upper respiratory tract infections (URTIs) and other respiratory disorders, along with the easy availability of cough syrups in general stores and pharmacies, is primarily driving the market growth.
Major Market Drivers: The expanding geriatric population who are more susceptible to developing respiratory disorders is primarily driving the market. Additionally, the increasing health consciousness among individuals is also acting as another significant growth-inducing factor.
Key Market Trends: Product manufacturers are introducing enhanced variants fortified with natural ingredients and herbs with immunity-boosting effects, which is one of the key trends propelling the global market. Besides this, the launch of cough syrups with minimal side effects is further strengthening the market.
Geographical Trends: Asia-Pacific currently dominates the global market, on account of the elevating healthcare expenditure capacities of individuals across the region. Apart from this, the growing focus on cough remedies is positively influencing the market growth.
Competitive Landscape: Some of the prominent cough syrup market companies include Acella Pharmaceuticals LLC, Bayer AG, GlaxoSmithKline PLC, Johnson & Johnson, Pfizer Inc., Prestige Consumer Healthcare Inc., Reckitt Benckiser Group PLC, Sanofi, Sun Pharmaceutical Industries Limited, and the Procter & Gamble Company, among many others.
Challenges and Opportunities: Primary challenges, such as the rising need to navigate a complex regulatory environment and the elevating concerns over the abuse and misuse of cough syrups containing opioids or other psychoactive ingredients, are hindering the overall market. However, the continuous growth of the pharmaceutical industry will continue to propel the global market in the coming years.
Growing Medical Conditions
The rising prevalence of cold, flu, bronchitis, pertussis, asthma, chronic pulmonary obstructive disease (COPD), and allergies is driving the need for cough syrups. For example, according to an article published by the Economic Times in 2023, around 339 million individuals are affected by asthma globally. Furthermore, the elevating cough cases, owing to the increasing tobacco consumption and unhealthy lifestyles, are also stimulating the market growth. Besides this, as per the World Health Organization (WHO), every year, more than 8 million people die prematurely from tobacco consumption. Among these, 7 million are direct smokers, and 1.7 million are second-hand smokers. Consequently, government and non-government organizations are launching numerous programs and campaigns to generate awareness among the population. For example, in July 2023, the Lung Foundation in Australia launched a chronic cough awareness campaign to raise awareness and support diagnosis in adults and pediatrics. In addition to this, the expanding geriatric population is further contributing to the cough syrup market outlook. For instance, according to the WHO, individuals aged 60 and above were 1 billion in 2020 and are expected to reach 2.1 billion by 2050.
Regulatory Environment by Government Bodies
Regulatory authorities across countries are implementing stringent rules to ensure leading companies of cough syrups comply with high medical standards. In line with this, they are generating awareness among healthcare professionals to develop generic drugs, thereby catalyzing the cough syrup market recent opportunities. For instance, in a letter written to all states and union territories, the Drugs Controller General of India (DCGI) asked to ensure that cough syrups produced in India are of global standard quality for which a detailed verification should be undertaken. In line with this, he asked for a joint verification drive on propylene glycol (PG) manufacturers, cough syrup manufacturers, and importers to ensure that the raw material utilized or supplied for the manufacturing of cough syrups is as per the global protocol. Additionally, the World Health Organization (WHO) has flagged another cough syrup for the presence of contaminants. The WHO tested a sample from a specific batch of the syrup after it received a report in July 2022 regarding possible contamination. Fourrts Laboratories produced the cough syrup on behalf of another company in India called Dabilife Pharma. These stringent regulations and checks will improve the quality of products, which is expected to propel the cough syrup market revenue in the coming years.
Strategic Alliances
Prominent key players are entering into mergers and acquisitions and are constantly working towards novel product developments that are usually formulated with natural ingredients and herbs with immunity-boosting effects. This, in turn, is driving the market forward. For example, in 2023, GSK plc. signed an acquisition deal with one of the Biotech firms in Canada, Bellus Health, for US$ 2 Billion. This deal was done to strengthen GSK's clinical pipeline portfolio and market position across the globe. The portfolio also included syrups and other formulations, thereby elevating the cough syrup market share. Similarly, in December 2023, the U.S. FDA issued a complete response letter (CRL) about Merck's new drug application (NDA) for gefapixant, one of the drugs to treat refractory chronic cough (RCC) in adults. Key players are further introducing cough syrups with natural ingredients to expand their consumer base, which is cough syrup market recent developments. For instance, Vitae Health Innovation launched VITATUSS, a natural syrup formulated with elderberry, thyme, althaea, mallow, and sea buckthorn extract. In line with this, Sun Pharmaceutical Industries Ltd. announced the introduction of a formulation in cough management called Chericof 12. The company said this was the first prescription cough syrup across India that offer relief for up to 12 hours.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on the product type, age group and distribution channel.
Expectorants
Cough Suppressants/Antitussives
Combination Medications
Currently, cough suppressants/antitussives account for the majority of the global market share
The report has provided a detailed breakup and analysis of the market based on the product type. This includes expectorants, cough suppressants/antitussives, and combination medications. According to the report, cough suppressants/antitussives accounted for the largest market share.
Symptoms related to cold and cough are usually managed by utilizing over the counter (OTC) medicines. Cough suppressants, or antitussive drugs, are medicines that are adopted to control and relieve a cough. While many antitussives are widely accessible OTC, a few antitussives are only available with a prescription. Antitussives are used in various types of formulations, such as capsules, liquids, tablets, and syrups. For example, Dextromethorphan, one of the most widely utilized cough suppressants in the U.S., was compared with codeine, the traditional antitussive in Europe, in a double-blind, crossover trial using both subjective and objective assessment of efficacy in sixteen patients with chronic cough. Dextromethorphan lowered cough intensity more than codeine and was considered the better antitussive by most patients. This, in turn, represents key factors propelling the cough syrup market growth in the segmentation.
Pediatric
Adult
Adult currently holds the largest market share
The report has provided a detailed breakup and analysis of the market based on the age group. This includes pediatric and adult. According to the report, adult accounted for the largest market share.
Adults commonly suffer from chronic and acute cough, owing to unhealthy lifestyles and high exposure to tobacco. For example, as per the study published by the European Respiratory Society in 2020, approximately 10% of the adult population suffers from chronic cough, on account of the impaired quality of life. Consequently, the expanding adult population is escalating the cough syrup market demand, thereby stimulating the adoption of cough remedies.
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
Currently, retail pharmacy exhibits a clear dominance in the market
The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes retail pharmacy, hospital pharmacy, and online pharmacy. According to the report, retail pharmacy accounted for the largest market share.
As per the cough syrup market overview, the easy product availability via distribution channels, such as retail pharmacy, owing to its accessibility and convenience, is bolstering the segmentation growth. For example, according to the Federal Union of German Associations of Pharmacists (ABDA, around 18,068 community pharmacies across Germany cater to medical needs in 2023. In addition to this, the rising number of generic and branded remedy products in retail pharmacy chains, including Walmart Stores Inc. and Walgreens, is further acting as another significant growth-inducing factor. Moreover, the increasing tie-ups of hospitals with these chains are strengthening the cough syrup market recent price.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
According to the cough syrup market statistics, Asia Pacific exhibits a clear dominance in the market
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific accounted for the largest market share.
The regional market is primarily driven by the numerous partnerships among pharmaceutical companies and government organizations, generally to develop novel generic drugs and generate awareness among individuals and healthcare professionals. Moreover, key players are emphasizing on innovative packaging solutions, which is contributing to the growth of the market. Apart from this, the inflating expenditure capacities of individuals across the region and the elevating focus on preventive healthcare are further validating the cough syrup market forecast. According to a report by the FMCG Gurus, more than 55% of people in the Asia Pacific region have been more conscious about boosting their immunity since the sudden outbreak of the COVID-19 pandemic.
Acella Pharmaceuticals LLC
Bayer AG
GlaxoSmithKline PLC
Johnson & Johnson
Pfizer Inc.
Prestige Consumer Healthcare Inc.
Reckitt Benckiser Group PLC
Sanofi
Sun Pharmaceutical Industries Limited
The Procter & Gamble Company
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
April 2024: The World Health Organization (WHO) issued a broader alert regarding contaminated children's cough syrup produced by Johnson and Johnson in response to the discovery of tainted batches in Nigeria.
March 2024: Nin Jiom, one of the Hong Kong-based companies known for its cough syrup product Pei Pa Koa, is venturing into the healthy aging supplement space with a nicotinamide mononucleotide (NMN) product set to launch in Singapore.
November 2023: Himalaya Wellness Company announced the launch of Himalaya Koflet's 360-degree advertising campaign to enhance brand awareness.